2025-11-12T17:11:23-06:00 2024-12-31 331374517 PKF O'CONNOR DAVIES ADVISORY LLC 245 PARK AVENUE 12TH FLOOR NEW YORK NY 10167 990 2024-01-01 133859563 THE ZACHARY & ELIZABETH M FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION ZACH 2129151328 750 LEXINGTON AVENUE 2400 NEW YORK NY 10022 BARRY R SLOANE CHAIRMAN & TREASURER 2129151328 2025-11-12 1 1 EVA MRUK P00543254 2122862600 2025-11-11 2024 2025-03-06 01:10:19Z ALZHEIMER'S RESEARCH FOUNDATIONFISHER CENTER BARRY R SLOANE 750 LEXINGTON AVENUE 2400 NEW YORK NY 10022 17116383 0 X WWW.ALZINFO.ORG X 1995 NY TO FUND RESEARCH INTO THE CAUSE, CARE, AND CURE OF ALZHEIMER'S DISEASE AT THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR RESEARCH ON ALZHEIMER'S DISEASE AT THE ROCKEFELLER UNIVERSITY IN NEW YORK THAT WAS UNDER THE DIRECTION OF NOBEL LAUREATE DR. PAUL GREENGARD WHOSE FINDINGS HAVE BEEN THE BASIS FOR MUCH OF TODAY'S ALZHEIMER'S INVESTIGATIONS. 10 10 11 10 0 0 9362648 13092793 3853 3085 1028395 1417748 74171 1992 10469067 14515618 4143657 19479990 0 0 980502 1201242 0 0 577938 1599178 1795845 6723337 22477077 3745730 -7961459 33358648 36263186 6303189 14243764 27055459 22019422 X THE ZACHARY AND ELIZABETH M. FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION IS DEDICATED TO ATTACKING THE SCOURGE OF ALZHEIMER'S DISEASE THROUGH A 3-PRONGED ASSAULT FOCUSED ON UNDERSTANDING THE CAUSE OF ALZHEIMER'S DISEASE (AD), IMPROVING THE CARE OF PEOPLE LIVING WITH THE DISEASE TO ENHANCE THEIR QUALITY OF LIFE AND THAT OF THEIR CAREGIVERS AND FAMILIES, AND FINDING A CURE. 0 0 5516050 5400000 0 NYU SCHOOL OF MEDICINE - FISHER CLINICAL TRIALS:NYU LANGONE CLINICAL TRIALS CONDUCTING 20 TRIALS ON EXPERIMENTAL ALZHEIMER'S TREATMENTS. MARTIN SADOWSKI, MD, PHD, PROVIDES PERSONALIZED COUNSELING FOR PARTICIPANTS, HELPING THEM FIND THE MOST SUITABLE TRIAL. 5107454 5000000 0 ROCKEFELLER UNIVERSITY ARTIFICIAL INTELLIGENCE PROGRAM:FISHER AI PLATFORM FOR ALZHEIMER'S & NEURODEGENERATIVE RESEARCH. THIS INITIATIVE EQUIPS NEUROSCIENTISTS WITH CUTTING-EDGE AI TOOLS TO ACCELERATE DISCOVERIES IN ALZHEIMER'S RESEARCH.USING AI TO MAP CELL LOSS AND DECODE GENE NETWORKSWITH THE SPONSORSHIP OF THE FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION, THE FISHER AI PLATFORM (LED BY DR. BARBANO) AND THE LABORATORY OF MOLECULAR BIOLOGY (LED BY DR. HEINTZ) APPLIED THEIR ADVANCED MFISH3D IMAGING TECHNIQUE TO TRACE HOW BRAIN CELLS ARE LOST OVER TIME IN ALZHEIMER'S DISEASE. THIS APPROACH ALLOWS RESEARCHERS TO SEE, IN THREE DIMENSIONS, WHICH TYPES OF BRAIN CELLS ARE MOST AFFECTED AND WHEN. IN PARALLEL, THE TEAM USED MACHINE LEARNING TO ANALYZE LARGE-SCALE GENETIC DATA, IDENTIFYING KEY NETWORKS OF GENES THAT MAY PLAY A ROLE IN BOTH ALZHEIMER'S AND HUNTINGTON'S DISEASE. THESE TOOLS PROVIDE A MORE DETAILED AND ACCURATE VIEW OF HOW THESE DISEASES PROGRESSAND WHERE TREATMENT MAY BE MOST EFFECTIVE.PREPARING FOR KISUNLA TREATMENT AT NYU LANGONEMARTIN SADOWSKI, MD, PHD, THE INAUGURAL INCUMBENT OF THE ZACHARY AND ELIZABETH M. FISHER PROFESSORSHIP IN NEURODEGENERATION AND ALZHEIMER'S DISEASE, WAS AN INVESTIGATOR ON ONE OF THE CLINICAL TRIALS OF KISUNLA (DONANEMAB), A NEW ALZHEIMER'S DRUG GRANTED FDA APPROVAL IN 2024. HE HAS SINCE DEVELOPED A TREATMENT PROTOCOL TO BE IMPLEMENTED ACROSS NYU LANGONE HEALTH. THE PROTOCOL OUTLINES HOW ELIGIBLE PATIENTS WITH EARLY-STAGE ALZHEIMER'S CAN ACCESS KINSUNLA AND BE MONITORED WHILE RECEIVING IT IN THERAPY. KISUNLA IS EXPECTED TO BE AVAILABLE TO NYU LANGONE PATIENTS BEGINNING IN JANUARY 2026. 3575218 3500000 0 ROCKEFELLER UNIVERSITY - FISHER CENTER LAB:NATHANIEL HEINTZ, PHD LEADS THE FISHER CENTER LAB AT THE ROCKEFELLER UNIVERSITY, HOME TO ONE OF THE LARGEST AND MOST ADVANCED ALZHEIMER'S RESEARCH FACILITIES IN THE WORLD. HIS TEAM STUDIES THE EARLIEST MOLECULAR EVENTS OF ALZHEIMER'SBEFORE AMYLOID-BETA (A) PLAQUES AND TAU TANGLES FORM. THEIR RESEARCH ON SELECTIVE CELLULAR VULNERABILITY AIMS TO UNCOVER WHY CERTAIN BRAIN CELLS DIE EARLIER THAN OTHERS, WHICH COULD BE KEY TO DEVELOPING TREATMENTS.AT THE FISHER CENTER LAB AT THE ROCKEFELLER UNIVERSITY, RESEARCHERS UNDER THE DIRECTION OF NATHANIEL HEINTZ, PHD, CONTINUE TO UNRAVEL THE EARLIEST MOLECULAR CHANGES IN ALZHEIMER'S DISEASE, AIMING TO UNDERSTAND WHAT MAKES CERTAIN BRAIN CELLS MOST VULNERABLE. BY PIONEERING CUTTING-EDGE MOLECULAR PROFILING TECHNIQUES, THEY ARE MAKING GROUNDBREAKING DISCOVERIES THAT PAVE THE WAY FOR BETTER TREATMENTS.RESEARCHERS AT THE FISHER CENTER LAB HAVE REFINED ADVANCED CELLULAR ANALYSIS METHODS TO EXAMINE HOW SPECIFIC BRAIN CELL TYPES ARE AFFECTED IN THE EARLIEST STAGES OF ALZHEIMER'S. THIS YEAR, THE TEAM: DEVELOPED NEW PROTOCOLS FOR ANALYZING HUMAN HIPPOCAMPUS AND ENTORHINAL CORTEX CELLS. IDENTIFIED EARLY-STAGE NEURON LOSS IN VULNERABLE BRAIN LAYERS, OFFERING INSIGHTS INTO DISEASE PROGRESSION. PROFILED 204 UNIQUE SAMPLES ACROSS 15 DIFFERENT CELL TYPES. UNCOVERED NEW TRANSCRIPTIONAL AND EPIGENETIC MARKERS THAT HELP EXPLAIN SELECTIVE CELLULAR VULNERABILITY.DATA-DRIVEN MILESTONE: THIS YEAR'S DATA HAVE CONFIRMED KNOWN PATTERNS OF DISEASE AND UNCOVERED NEW MOLECULAR EVENTS THAT SHED LIGHT ON HOW ALZHEIMER'S PROGRESSES AT THE CELLULAR LEVEL.UNDERSTANDING DISEASE PROGRESSION WITH NEW STAGING TOOLS:ONE CHALLENGE IN ALZHEIMER'S RESEARCH IS ACCURATELY DETERMINING DISEASE STAGE IN DONOR BRAIN SAMPLES. THE FISHER CENTER LAB HAS NOW DEVELOPED AN IN-HOUSE BRAAK STAGING PLATFORM, ENSURING THAT MOLECULAR FINDINGS ARE PROPERLY CONTEXTUALIZED.RECENT DISCOVERIES: THE EARLIEST DETECTABLE CHANGE OCCURS IN LAYERS 2/3 AND 4 OF THE CORTEX, REINFORCING THEIR SUSCEPTIBILITY. NO SIGNIFICANT LOSS WAS OBSERVED IN LAYER 5A PYRAMIDAL CELLS, A KEY DISTINCTION BETWEEN ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES. COMPUTATIONAL AND BIOINFORMATICS TOOLS ARE BEING APPLIED TO COMPARE MOLECULAR CHANGES IN VULNERABLE VS. RESISTANT NEURONS. 3108409 2916596 3085 FISHER CENTER ASSISTANT PROFESSORSHIP (CAO):THE FISHER CENTER FOUNDATION INFORMATION PROGRAM DESCRIPTION AND ACCOMPLISHMENTSJUNYUE CAO, PHD RECIPIENT OF THE FISHER CENTER FOR ALZHEIMER'S RESEARCH FOUNDATION ASSISTANT PROFESSORSHIP, DR. CAO IS USING ADVANCED GENOMICS AND AI-DRIVEN ANALYSIS TO STUDY HOW GENE EXPRESSION AND EPIGENETICS INFLUENCE ALZHEIMER'S PROGRESSION.TRACKING BRAIN CELL CHANGES OVER TIMEJUNYUE CAO, PHD, WAS APPOINTED AS THE ROCKEFELLER UNIVERSITY'S FIRST FISHER CENTER FOUNDATION ASSISTANT PROFESSOR, A ROLE SUPPORTED BY THE ZACHARY AND ELIZABETH M. FISHER FUND FOR TRANSLATIONAL RESEARCH IN ALZHEIMER'S AND NEUROGENERATIVE DISEASE. HIS LAB DEVELOPED TRACKERSCI, A POWERFUL NEW TECHNIQUE THAT ALLOWS SCIENTISTS TO OBSERVE HOW BRAIN CELLS CHANGE ACROSS DIFFERENT STAGES OF LIFE. BY LABELING AND TRACKING TENS OF THOUSANDS OF INDIVIDUAL BRAIN CELLS, THE METHOD REVEALS HOW CERTAIN TYPES OF CELLS DECREASE WITH AGE WHILE OTHERS ESPECIALLY INFLAMMATORY CELLS BECOME MORE COMMON. THESE INSIGHTS COULD HELP RESEARCHERS BETTER UNDERSTAND THE EARLY BIOLOGICAL CHANGES THAT LEAD TO ALZHEIMER'S DISEASE. A PATENT APPLICATION FOR TRACKERSCI HAS BEEN FILED. 3329638 2663394 0 NYU SCHOOL OF MEDICINE PROFESSORSHIP (SADOWSKI):DR. SADOWSKI THE ZACHARY AND ELIZABETH M. FISHER ENDOWED PROFESSOR IN NEURODEGENERATION AND ALZHEIMER'S DISEASE AT NYU, DR. SADOWSKI STUDIES GLIAL CELL DYSFUNCTION AND THE PROTECTIVE EFFECTS OF PEROXIREDOXIN 6, A POTENTIAL ALZHEIMER'S THERAPY.AT NYU GROSSMAN SCHOOL OF MEDICINE'S 2024 DEAN'S HONORS DAY, DR. SADOWSKI WAS FORMALLY RECOGNIZED WITH THE APPOINTMENT AS THE INAUGURAL ZACHARY AND ELIZABETH M. FISHER PROFESSOR OF NEURODEGENERATION AND ALZHEIMER'S DISEASE. THIS PRESTIGIOUS RECOGNITION CELEBRATES HIS DISTINGUISHED ACCOMPLISHMENTS IN ALZHEIMER'S RESEARCH AND HIS PROFOUND CONTRIBUTIONS TO NYU LANGONE'S ACADEMIC AND CLINICAL MISSION.THE NEW PROFESSORSHIP WILL SUPPORT DR. SADOWSKI'S ONGOING TRANSLATIONAL RESEARCH INTO THE CAUSES OF ALZHEIMER'S DISEASE. IT ALSO COINCIDES WITH THE LAUNCH OF THE FISHER CENTER ALZHEIMER'S CLINICAL TRIALS PROGRAM AT NYU LANGONE HEALTH, WHICH EXPANDS ACCESS TO EMERGING THERAPIES AND ENABLES INVESTIGATOR-LED TRIALS FOCUSED ON PREVENTION. AS BOTH A CLINICIAN AND RESEARCHER, DR. SADOWSKI CONTINUES TO ADVANCE THE FIELD AND BRING NEW HOPE TO PATIENTS AND FAMILIES AFFECTED BY ALZHEIMER'S. 6438047 5579990 3085 20636769 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 17 0 11 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL CA FL GA HI IL KS KY MA MD MI MN MS NH NY OR RI SC TN WV X X X LUCRETIA HOLDEN 2129151328 750 LEXINGTON AVENUE SUITE 2400 NEW YORK NY 10022 BARRY R SLOANE CHAIRMAN/TREASURER 5.00 X X 0 0 0 MARTIN EDELMAN VICE CHAIRMAN 0.25 X X 0 0 0 DAVID HW TURNER VICE CHAIRMAN 5.00 X X 0 0 0 HADLEY M FISHER SECRETARY 5.00 X X 0 0 0 DR MANUEL ALVAREZ TRUSTEE 5.00 X 0 0 0 GERRY BYRNE TRUSTEE 5.00 X 0 0 0 BETSY GOTBAUM TRUSTEE 0.50 X 0 0 0 JAMES L NEDERLANDER TRUSTEE 0.25 X 0 0 0 RICHARD J SALEM TRUSTEE 0.75 X 0 0 0 DR MOSHE SHIKE TRUSTEE 0.25 X 0 0 0 LUCRETIA HOLDEN EXECUTIVE DIRECTOR 40.00 X 336398 0 37112 JERRY LOUIS CREATING MARKETING MANAGER 40.00 X 111434 0 8160 REBECCA A LIBED OPERATIONS MANAGER 40.00 X 111583 0 28343 ELIZABETH MCHALEY INFORMATION PROGRAM DIR. THRU 11/24 40.00 X 103354 0 22732 662769 0 96347 4 0 1 0 THE STAYWELL COMPANY LLC PO BOX 90477 CHICAGO IL 606960477 PUBLISHING SERVICES 204037 CENTURY DIRECT SOLUTIONS LLC 15 ENTER LANE ISLANDIA NY 11749 DIRECT MAIL MARKETING AND PRINTING SERVI 126348 YOUR PART-TIME CONTROLLER LLC 1600 MARKET STREET SUITE 3425 PHILADELPHIA PA 19103 ACCOUNTING SERVICES 126268 ELITE ACCOUNTING SERVICES LLC 500 MAMARONECK AVENUE HARRISON NY 10528 BOOKKEEPING SERVICES 110938 CORE STAFFING SERVICES INC 463 SEVENTH AVENUE SUITE 1800 NEW YORK NY 10018 TEMPORARY STAFFING 103847 5 71014 13021779 1568529 13092793 MAGAZINE SUBSCRIPTIONS 900099 3085 3085 3085 576268 576268 3442245 2600765 841480 841480 841480 REBATES 900099 1992 1992 1992 14515618 3085 0 1419740 19351990 19351990 128000 128000 373510 186755 37351 149404 661616 379541 75494 206581 24978 14413 2866 7699 73651 41186 8200 24265 67487 37018 7376 23093 38295 38295 257283 257283 109192 109192 172912 50011 32233 90668 109542 109542 223320 119845 52455 51020 45340 38217 7123 250896 15546 228768 6582 6704 1000 5277 427 9204 8468 460 276 15373 15373 PRINTING AND PUBLISHING 280375 280375 TEMPORARY STAFF RECRUIT 148818 148818 DUES & SUBSCRIPTIONS 59536 2548 49816 7172 CREDIT CARD PROCESSING 23994 1027 20077 2890 45061 19046 25277 738 22477077 20636769 1262370 577938 4866111 3300904 749789 1300204 411989 384885 5084 5084 129928 42694 74450 34404 39206 40046 24804968 28987964 159467 186692 2192106 2014713 33358648 36263186 186434 242558 3970874 12022864 2145881 1978342 6303189 14243764 X 26954613 21948408 100846 71014 27055459 22019422 33358648 36263186 X -7961459 2959475 -34053 X X 0 1 X 1 0 X 7435201 8297600 7359644 9362648 13092793 45547886 7435201 8297600 7359644 9362648 13092793 45547886 6699426 38848460 383515 422331 497623 489256 576268 2368993 385 2643 74171 1992 79191 47996070 11249 0.80940 0.86060 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2020 AMOUNT: $ 385. 2021 AMOUNT: $ 2,643. 2023 AMOUNT: $ 2,637. 2024 AMOUNT: $ 1,992. RENT REIMBURSEMENT - 2023 AMOUNT: $ 71,534. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 74450 34404 40046 40046 SECURITY DEPOSIT 53615 RIGHT OF USE ASSET 1961098 2014713 LEASE LIABILITY 1978342 1978342 X 17484850 2959475 118949 3078424 14406426 109192 109192 14515618 22520887 118949 34053 153002 22367885 109192 109192 22477077 PART X, LINE 2: THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE FOUNDATION HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. THE FOUNDATION IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR TAX YEARS PRIOR TO 2021. PART XII, LINE 2D - OTHER ADJUSTMENTS: WRITE-OFF OF UNCOLLECTABLE PLEDGES 34,053. 1 EUROPE 0 0 GRANT TO RECIPIENT LOCATED IN THE REGION 128000 0 0 0 0 0 0 128000 0 128000 EUROPE (INCLUDING ICELAND & GREENLAND) ALZHEIMER'S RESEARCH 128000 WIRE 0 1 0 0 0 0 0 0 PART I, LINE 2: A SINGLE GRANT WAS GIVEN TO A RESEARCH INSTITUTE IN EUROPE FOR PROGRAM-RELATED RESEARCH. THE GRANTEE ORGANIZATION PROVIDED THE ORGANIZATION WITH AN INTERIM SIX MONTH REPORT ON THE PROGRESS OF THEIR INVESTIGATIONS, AS WELL AS A FINAL REPORT AT THE END OF THE AGREEMENT. PART I, LINE 3: THE ORGANIZATION USES THE ACCRUAL METHOD OF ACCOUNTING TO ACCOUNT FOR ITS FOREIGN EXPENDITURES. 1 THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 10951990 0 TO FUND ALZHEIMER'S DISEASE RESEARCH. SEE PART IV FOR DETAILS. NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562309 501(C)(3) 8400000 0 TO FUND ALZHEIMER'S DISEASE RESEARCH. SEE PART IV FOR DETAILS. 2 PART I, LINE 2: THE ORGANIZATION MONITORS THE USE OF GRANT FUNDS IN THE U.S. BY RECEIVING PERIODIC PROGRESS REPORTS ON THE RESEARCH CONDUCTED AND ANY FINDINGS PUBLISHED AS A RESULT OF THE FUNDING. THE GRANT DECISIONS ARE MADE UNDER THE SOLE AND ABSOLUTE DISCRETION OF THE BOARD PURSUANT TO A MAJORITY VOTE. ADDITIONALLY, NEW YORK UNIVERSITY PREPARES A RESEARCH PRESENTATION DURING AT LEAST ONE OF THE BOARD MEETINGS DURING THE CALENDAR YEAR. NYU ALSO PROVIDES THE FOUNDATION WITH A WRITTEN REPORT. FORM 990, SCHEDULE I, PART II, COLUMN (H): PURPOSES OF GRANTS TO THE ROCKEFELLER UNIVERSITY: THE ROCKEFELLER UNIVERSITY FISHER CENTER FOR ALZHEIMER'S RESEARCH LAB: THIS GRANT FUNDS NEUROLOGICAL RESEARCH INTO THE CAUSE(S) OF ALZHEIMER'S, AND POTENTIAL NEW PHARMACOLOGICAL TREATMENT OPTIONS, AND TO SUPPORT PROFESSORSHIPS TO CONDUCT RESEARCH ACTIVITIES. THE ZACHARY AND ELIZABETH M. FISHER PROFESSORSHIP IN ALZHEIMER'S AND NEURODEGENERATIVE DISEASE: THIS GRANT FUNDS A PROFESSORSHIP NAMED FOR THE ORGANIZATION'S FOUNDERS THAT ADVANCES THE UNDERSTANDING OF AND TREATMENT FOR ALZHEIMER'S AND OTHER DEBILITATING DISEASES. THIS PROFESSORSHIP IS CURRENTLY HELD BY DR. SIDNEY STRICKLAND WHO HEADS THE UNIVERSITY'S PATRICIA AND JOHN ROSENWALD LABORATORY OF NEUROBIOLOGY AND GENETICS. THE ROCKEFELLER UNIVERSITY GREENGARD PROFESSORSHIP IN NEUROSCIENCE: THIS GRANT HONORS NOBEL LAUREATE DR. PAUL GREENGARD AND THE NEARLY 25 YEARS HE SPENT AS DIRECTOR FOR THE ZACHARY AND ELIZABETH M. FISHER CENTER ON ALZHEIMER'S RESEARCH LAB AT THE ROCKEFELLER UNIVERSITY BEFORE HIS DEATH IN 2019. THE NAMED CHAIR WILL BE SOMEONE WHO HONORS GREENGARD'S LEGACY IN CONDUCTING RESEARCH TO FIND A CURE FOR ALZHEIMER'S DISEASE. X X X 1 0 0 0 0 0 0 1 0 LUCRETIA HOLDEN EXECUTIVE DIRECTOR 236033 0 100000 0 365 0 14663 0 22449 0 373510 0 0 0 PART I, LINE 4A ELIZABETH MCHALEY RECEIVED SEVERANCE PAYMENT OF $7,312. PART I, LINE 7: THE ORGANIZATION PAID DISCRETIONARY BOARD-APPROVED BONUSES IN 2024. THE AMOUNTS ARE REPORTED IN PART II, COLUMN B(II). X 25 1568529 AVG SELLING PRICE 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN COLUMN (B). FORM 990, PART VI, SECTION B, LINE 11B THE 990 IS INITIALLY REVIEWED BY MEMBERS OF THE AUDIT COMMITTEE THAT CONSISTS OF 3 INDEPENDENT TRUSTEES. A COPY IS THEN FORWARDED ELECTRONICALLY TO ALL BOARD MEMBERS AND RELEVANT MANAGEMENT PERSONNEL FOR THEIR REVIEW AND COMMENT. ANY REQUIRED REVISIONS ARE MADE AND THE REVISED 990 IS RESUBMITTED TO ALL BOARD MEMBERS FOR FINAL REVIEW BEFORE FILING. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION HAS A CONFLICT OF INTEREST POLICY WHICH IS ANNUALLY MONITORED REQUIRING ALL TRUSTEES TO DISCLOSE ANY POSSIBLE CONFLICT OF INTEREST VIA EMAIL RESPONSE TO THE EXECUTIVE DIRECTOR. THE FOUNDATION REQUIRES THAT ALL TRUSTEES, OFFICERS, KEY EMPLOYEES AND STAFF PERSONNEL PROMPTLY AND FULLY DISCLOSE ALL MATERIAL FACTS OF ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST THAT MAY EXIST AT THE TIME THE TRUSTEE IS APPOINTED OR STAFF PERSONNEL IS HIRED, OR AS THEY MAY ARISE WHILE THE TRUSTEE IS SERVING ON THE BOARD OR THE STAFF PERSONNEL IS EMPLOYED BY THE FOUNDATION. SUCH DISCLOSURES INVOLVING A TRANSACTION, ARRANGEMENT OR DECISION BEING CONSIDERED BY THE BOARD ARE MADE KNOWN TO ALL TRUSTEES. THE BOARD THEN DETERMINES WHETHER A CONFLICT OF INTEREST EXISTS WITH THE INTERESTED PARTY ABSTAINING FROM THE DECISION. IF IT IS DETERMINED THAT A CONFLICT EXISTS, THEN THE BOARD VOTES ON THE TRANSACTION BUT WITH THE INTERESTED PARTY RECUSING HIMSELF FROM THE DISCUSSION AND VOTE ON SAID MATTER. FORM 990, PART VI, SECTION B, LINE 15A THE FOUNDATION HAS A COMPENSATION COMMITTEE CONSISTING OF THE CHAIRMAN/TREASURER AND VICE CHAIRMAN MANDATED BY ITS CHARTER TO REVIEW THE EXECUTIVE AND OTHER KEY EMPLOYEE PERFORMANCE APPRAISAL CONSISTENT WITH THE GOALS AND OBJECTIVES OF THE FOUNDATION. AT LEAST ONCE A YEAR, THE COMMITTEE IS MANDATED BY ITS CHARTER TO REVIEW EXECUTIVE DIRECTOR'S PERFORMANCE CONSISTENT WITH THE GOALS AND OBJECTIVES OF THE FOUNDATION AS DETERMINED BY THE BOARD OF TRUSTEES, AND TO DETERMINE AN APPROPRIATE LEVEL OF COMPENSATION IN LIGHT OF THIS PERFORMANCE REVIEW AND USING OTHER SUBSTANTIATING DATA SURVEYS ON CURRENT COMPENSATION RATES FOR SIMILAR POSITIONS IN OTHER COMPARABLE NONPROFITS IN THE NEW YORK CITY AREA. THE COMMITTEE'S DECISION IS DOCUMENTED IN A CONTEMPORANEOUSLY WRITTEN FORMAT (COMPENSATION COMMITTEE MINUTES) INDICATING THE DATE OF THE MEETING, THE MEMBERS PRESENT, AND THE COMPARABLE DATA USED TO MAKE THE DECISION. THE COMPENSATION REVIEW PROCESS FOR THE EXECUTIVE DIRECTOR WAS LAST UNDERTAKEN IN NOVEMBER 2024. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION MAKES ITS FORM 990 AND AUDITED FINANCIAL STATEMENTS AVAILABLE FOR PUBLIC INSPECTION BY POSTING ON THEIR WEBSITE. IN ADDITION, THE ORGANIZATION'S GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9: WRITE-OFF OF UNCOLLECTABLE PLEDGES -34,053. FORM 990, PART XII, LINE 2C: THE FOUNDATION HAS AN AUDIT COMMITTEE THAT IS RESPONSIBLE FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND THE SELECTION OF AN INDEPENDENT ACCOUNTANT. THE PROCESS HAS NOT CHANGED FROM THE PREVIOUS YEAR.